First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Part of paid clinical trials in Sarasota, Florida.

Sponsor
Daiichi Sankyo
Study ID
NCT05875168
Phase
PHASE1/PHASE2
Status
Recruiting

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DS-3939a — DRUG
    One IV infusion Q3W on Day 1 of each 21-day cycle

Study Details

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

Key Dates

Start date
Aug 18, 2023
Status verified
Apr 2026
Primary completion
Oct 20, 2026
Completion
Feb 15, 2027

Study Design

Enrollment
540 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation (Part 1)
    Participants with locally advanced, metastatic, or unresectable tumors who will receive an intravenous (IV) infusion of DS-3939a.
  • Experimental: Dose Expansion (Part 2)
    Multiple expansion cohorts targeting various advanced solid tumors.

Primary Outcome Measure

Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939a [ Time Frame: Approximately 3 months after first dosing ]

Central Contacts

  • (US Sites) Daiichi Sankyo Contact for Clinical Trial Information
    908-992-6400
  • (Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
    +81-3-6225-1111 (M-F 9-5 JST)

Locations (6)

FacilityCityStateZIPSite coordinators
Florida Cancer SpecialistsSarasotaFlorida34232
Principal Investigator
Oregon Health & Science UniversityPortlandOregon97239-
Rhode Island HospitalProvidenceRhode Island02903
Principal Investigator
University of Texas M.D. Anderson Cancer CenterHoustonTexas77030-
Huntsman Cancer Institute, University of UtahSalt Lake CityUtah84112
Principal Investigator
The Medical College of Wisconsin, INCMilwaukeeWisconsin53226-

Find similar trials in Sarasota, FL

Related Studies